While the approach lost some of its luster after failing to deliver on early hype, technological improvements are revitalizing interest among researchers.
A study presented at ASHG Tuesday showed that newly identified schizophrenia risk genes appear to have some overlap with genes involved in autism spectrum disorder.
The study is one of several recent efforts to detect bacteria directly with mass spec, which could eliminate the need for culturing and speed turnaround time.
Join MNG Laboratories' Chief Medical Officer, Dr. Peter L. Nagy, and the Clinical Reporting Team as they present multiple case studies illustrating the value of using complementary testing and data analysis methods to increase the clinical sensitivity of MNG’s genetic testing portfolio. The team will highlight cases solved through the application of high resolution CNV assessment, mitochondrial DNA analysis, transcriptome/RNA sequencing, and repeat expansion screening from genome sequencing datasets. After the presentation, there will be a 15 minute Q&A with our speakers.
Join us for a webinar presented by our Chief Medical Officer, Dr. Peter L. Nagy, to discuss the benefits of performing and analyzing genome and RNA sequencing together. The increased number of single nucleotide and copy number variants associated with genome sequencing are best interpreted with the help of joint parental testing and the assessment of the functional significance of intronic and regulatory changes with a functional test like the transcriptome.
